FDA-Approved vs. Compounded vs. Research

A small number of peptides have undergone the full FDA approval process, including Phase I, II, and III clinical trials. Examples include Tesamorelin (Egrifta) for HIV lipodystrophy and Bremelanotide (Vyleesi) for HSDD. These compounds have the strongest evidence base and most well-characterized safety profiles. FDA approval means the compound has been rigorously tested for safety and efficacy in its approved indication. However, it does not mean it has been tested for every possible use — off-label use carries different risk-benefit considerations.

Many peptides are available through compounding pharmacies, which create customized medications under clinician prescription. Compounded peptides are legal when prescribed by a licensed clinician and prepared by a licensed compounding pharmacy. However, compounded medications do not undergo the same rigorous testing as FDA-approved drugs. Quality can vary between pharmacies, and the specific formulations may differ from what was used in research studies. Choosing a reputable compounding pharmacy that follows current Good Manufacturing Practices (cGMP) is essential.

Some peptides are available primarily as 'research chemicals' — compounds sold for laboratory research purposes. These have the least regulatory oversight and the highest quality control risk. Using research-grade compounds for personal use carries significant risks including contamination, incorrect dosing, and unknown purity. This resource does not recommend using research-grade compounds for personal use. If you are interested in a peptide that is only available as a research compound, discuss this with a qualified clinician who can help assess the risk-benefit ratio.

The regulatory status of a peptide directly affects the confidence you can have in its safety and quality. FDA-approved peptides have been tested in thousands of patients. Compounded peptides rely on the quality systems of individual pharmacies. Research compounds may have minimal quality assurance. When evaluating any peptide, always consider: What is its regulatory status? What is the quality of the source? Has it been tested in humans? And is a qualified clinician involved in the decision?